financetom
Business
financetom
/
Business
/
Travel + Leisure Q2 Adjusted Earnings, Net Revenue Rise; Offers Q3, Full Year Adjusted EBITDA Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Travel + Leisure Q2 Adjusted Earnings, Net Revenue Rise; Offers Q3, Full Year Adjusted EBITDA Guidance
Jul 24, 2024 4:34 AM

07:02 AM EDT, 07/24/2024 (MT Newswires) -- Travel + Leisure ( TNL ) reported Q2 adjusted earnings Wednesday of $1.52 per diluted share, up from $1.33 a year earlier.

Analysts polled by Capital IQ expected $1.41.

Net revenue for the quarter ended on June 30 was $985 million, up from $949 million a year earlier.

Analysts surveyed by Capital IQ expected $987.2 million.

The company expects Q3 adjusted EBITDA of $235 million to $245 million. Analysts polled by Capital IQ expect $238.7 million. The company updated its full-year adjusted EBITDA to a new range of $915 million to $935 million versus the prior outlook of $910 million to $930 million. Analysts polled by Capital IQ expect $921.6 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lightwave Logic Extends CEO's Tenure Until 2028; Announces CFO, COO Retirement
Lightwave Logic Extends CEO's Tenure Until 2028; Announces CFO, COO Retirement
Sep 16, 2025
05:23 PM EDT, 09/16/2025 (MT Newswires) -- Lightwave Logic ( LWLG ) said late Tuesday its board and Chief Executive Yves LeMaitre have agreed to extend his employment term until the end of 2028. The electro-optic polymer materials company's Chief Financial Officer and Chief Operating Officer Jim Marcelli will also be retiring at the end of 2025. Lightwave said it...
Kura Oncology Hosts Event Focused on Farnesyl Transferase Inhibitor Program
Kura Oncology Hosts Event Focused on Farnesyl Transferase Inhibitor Program
Sep 16, 2025
05:27 PM EDT, 09/16/2025 (MT Newswires) -- Kura Oncology ( KURA ) said Tuesday it is hosting the first of two events for analysts and investors focused on its farnesyl transferase inhibitor, or FTI, program. The event will feature preclinical data showing the potential of FTIs to improve the anti-tumor activity of targeted treatments in diverse tumor types, the company...
Globus Medical Insider Sold Shares Worth $584,600, According to a Recent SEC Filing
Globus Medical Insider Sold Shares Worth $584,600, According to a Recent SEC Filing
Sep 16, 2025
05:22 PM EDT, 09/16/2025 (MT Newswires) -- Ann D Rhoads, Director, on September 15, 2025, sold 10,000 shares in Globus Medical ( GMED ) for $584,600. Following the Form 4 filing with the SEC, Rhoads has control over a total of 25,384 Class A common shares of the company, with 25,384 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1237831/000119312525205135/xslF345X05/ownership.xml ...
BRIEF-Rail Customer Coalition Sends Letter To Surface Transportation Board Raising Concerns Over Union Pacific-Norfolk Deal
BRIEF-Rail Customer Coalition Sends Letter To Surface Transportation Board Raising Concerns Over Union Pacific-Norfolk Deal
Sep 16, 2025
Sept 16 (Reuters) - Norfolk Southern Corp ( NSC ): * RAIL CUSTOMER COALITION IN LETTER TO SURFACE TRANSPORTATION BOARD: EXPRESSING CONCERNS & RESERVATIONS ABOUT UNION PACIFIC-NORFOLK DEAL * RCC IN LETTER TO STB: BOARD MUST RIGOROUSLY EVALUATE POTENTIAL IMPACTS OF UNION PACIFIC-NORFOLK DEAL * RCC IN LETTER TO STB: OUR ORGANIZATIONS ARE COMMITTED TO ACTIVELY ENGAGING IN STB REVIEW...
Copyright 2023-2026 - www.financetom.com All Rights Reserved